Aim: To identify the barriers and facilitators to start insulin in patients with type 2 diabetes. Method: This was a systematic review. We conducted a systematic search using PubMed, EMBASE, CINAHL and Web of Science (up to 5 June 2014) for original English articles using the terms 'type 2 diabetes', 'insulin', and free texts: 'barrier' or 'facilitate' and 'initiate'. Two pairs of reviewers independently assessed and extracted the data. Study quality was assessed with Qualsyst. Results: A total of 9740 references were identified: 41 full-text articles were assessed for eligibility. Twenty-five articles (15 qualitative, 10 quantitative) were included in the review. Good inter-rater reliability was observed for the Qualsyst score (weighted kappa 0.7). Three main themes identified were as follows: patient-related, healthcare professional and system factors. The main patientrelated barriers were fear of pain and injection (n = 18), concerns about side effects of insulin (n = 12), perception that insulin indicated end stage of diabetes (n = 11), inconvenience (n = 10), difficulty in insulin administration (n = 7), punishment (n = 7) and stigma and discrimination (n = 7). Healthcare professionals' barriers were as follows: poor knowledge and skills (n = 9), physician inertia (n = 5) and language barriers (n = 4). System barriers included lack of time (n = 5). The most common facilitators were understanding the benefits of insulin (n = 7), not being afraid of injections (n = 5), and patient education and information (n = 5). Conclusion: Major barriers to insulin initiation persist despite availability of newer and safer insulin. Healthcare professionals should explore and address these barriers. Targeted interventions should be developed to overcome these barriers.
Introduction
Clinicians face challenges when advising patients with type 2 diabetes to start insulin, particularly in patients who have poor glycaemic control despite maximal oral glucose-lowering drugs. Up to 27% of patients are reluctant to start insulin when advised to do so (1) (2) (3) (4) . This is despite clear evidence that good glycaemic control reduces micro-vascular, and to a lesser degree, macro-vascular complications (5) .
There are many reasons why patients are hesitant to start insulin. This resistance to initiate insulin has been termed 'psychological insulin resistance' (4, 6, 7) . Patients' concerns can be categorised into copingoriented and knowledge-based barriers (3) . Copingoriented barriers include negative feelings and phobias like depression, anxiety and embarrassment, feelings of failure, lack of confidence and needle phobia. Knowledge-based barriers include myths or misperceptions about insulin including addiction concerns, doubting the effectiveness of insulin, fear of hypoglycaemia and inadequate knowledge of glycaemic targets (3) .
Healthcare professionals face new challenges when using insulin because of evolving clinical evidence. For example, recent studies show that tight glycaemic control, particularly for those on insulin, does not reduce cardiovascular events and may increase mortality (8) . This contradicts the previous guidelines which recommend tight glycaemic control as the standard of care for type 2 diabetes. It is now recommended that glucose-lowering drugs should be titrated according to patient clinical profiles and their psychosocial background (8) . This can result in clinical dilemmas on when to initiate insulin for individual patients. It is therefore important to consider the barriers and facilitators to insulin initiation when counselling patients who are making decisions about starting insulin.
Therefore, this systematic review aimed to identify the barriers and facilitators to insulin initiation in patients with type 2 diabetes. We believe this will help clinicians in counselling their patients when starting insulin. Figure 1 shows the selection and reviewing process of this systematic review. A comprehensive search was conducted using PubMed, Embase, CINAHL and Web of Science (search dates: up to 5 June 2014) for all studies on barriers and facilitators to initiating insulin in patients with type 2 diabetes. We used Medical Subject Headings (MeSH) 'type 2 diabetes' and 'insulin' as well as text word searches such as 'barrier' (or similar terms like 'obstacle' or 'hurdle' or 'limit' or 'problem' or 'difficult' or 'hindrance') and 'facilitate' (or similar terms like 'aid' or 'assist' or 'support' or 'encourage' or 'promote' or 'motivate') and (initiat* OR start* OR begin* OR introduc*). The search strategy can be found in the Appendix 1.
Methods

Inclusion and exclusion criteria
Published articles which met the following criteria were included: qualitative or quantitative studies; original articles; conducted in a healthcare setting; published in English; focused on patients with type 2 diabetes who are insulin na€ ıve; and barriers and/or facilitators. Only full text articles were included in the review. Duplicates were identified and excluded.
Data extraction and synthesis
Four reviewers worked independently in pairs to assess and extract data from each included study. The study quality was assessed using the QualSyst scoring system which is a validated tool incorporating both quantitative and qualitative research appraisal (Appendix 1) (9) . Scores ranged from 0 to 1 where a higher score indicates higher quality. Intraclass correlation coefficients were calculated to determine inter-rater agreement for both quantitative and qualitative papers. Any discrepancy was resolved through discussion. We identified barriers and facilitators from all studies, both quantitative and qualitative, and managed the data using NVivo version 9 from QSR International (Melbourne, Australia). For quantitative studies, the prevalence of barriers and facilitators were extracted where available.
Results
A total of 25 articles were included in this review ( Figure 1 ).
Study characteristics
Seven studies were conducted in the United Kingdom (10) (11) (12) (13) (14) (15) (16) , three in the United States of America (17) (18) (19) , two studies in Malaysia (20, 21) , Singapore (22, 23) , and South Africa (24, 25) , and one in Australia (26) , Belgium (27) , Canada (28), Israel (29) , Japan (30) and Romania (31) . Three studies were conducted in multiple countries including one involving 13 countries across the world (2), one in USA and Canada (32) and one in nine Arabic countries (33) . Eleven studies were conducted in clinics (10, 16, 17, (22) (23) (24) (25) (26) (27) (28) (29) , five in hospitals (11) (12) (13) 20, 30) , three in both the clinics and hospitals (14, 15, 18) , three in both clinics and academic centres (19, 21, 32) , while three did not specify their setting (2, 31, 33) .
Seven studies involved patients (11, 12, 18, 20, 23, 24, 31) , six studies involved doctors (17, 25, 27, 28, 32, 33) and three involved nurses (10, 14, 15) . Six studies included doctors and nurses (2, 13, 16, 19, 27, 28) , two studies included doctors and patients (29, 30) , two studies included doctors, nurses and patients (22, 26) and one study included all relevant healthcare professional stakeholders such as doctors, nurses and government policy makers (21) .
Thirteen studies identified barriers to insulin initiation (2, 12, 14, 18, (20) (21) (22) 25, (28) (29) (30) 32, 33) ; two studies identified facilitators to insulin initiation (10, 11) ; and 10 studies identified both barriers and facilitators to insulin initiation (13, (15) (16) (17) 19, 23, 24, 26, 27, 31) (Table 1 ).
Quality assessment of included studies
A total of 15 qualitative studies (10) (11) (12) (13) (14) (15) (16) (20) (21) (22) (25) (26) (27) (28) 31 ) and 10 quantitative studies (2, (17) (18) (19) 23, 24, 29, 30, 32, 33) were identified in this review.
Overall, most of the studies were of good quality and we included all 25 studies in the analysis. Final QualSyst score (maximum 1.0) ranged from 0.70 to 1.00 for quantitative studies, and 0.55-0.93 for qualitative studies. The weighted kappa was 0.7 (95% CI 0.6-0.8).
Qualitative studies
Nine studies used in-depth interviews (10, 11, (13) (14) (15) 20, 26, 27, 31) , four used focus group discussions (12, 16, 22, 28) and two used both (21, 25) . Sample size ranged from 4 to 66 participants. Only three studies stated their theoretical frameworks: normalisation process model (26) , implementation model (27) , and Heideggerian hermeneutic phenomenology (14) . Sampling methods used were mainly purposive (10) (11) (12) (13) (14) (15) (20) (21) (22) (25) (26) (27) 31) and convenient (28) . However, one study used both purposive and convenient sampling (16) . Type of analyses used were thematic (12, (14) (15) (16) (20) (21) (22) 25, 27) and content (10, 31) analysis. Four studies did not specify the analysis method used (11, 13, 26, 28) .
Quantitative studies
Nine cross-sectional (2, (17) (18) (19) 23, 24, 30, 32, 33) and one case-control (29) studies were included in this review. Response rates ranged from 19.8% to 100%. Sample size ranged from 68 to 3396 participants. (Table 1 )
Research instruments used in surveys
None of the quantitative studies provided information on the validation of the instrument they used. Seven of 10 studies used self-designed questionnaires (17, 19, 23, 29, 30, 32, 33) and three did not specify the instrument they used (2,18,24; Table 2 ).
Barriers and facilitators to insulin initiation
Barriers and facilitators can be divided into three categories: patient-related, healthcare professional and system factors. The most commonly reported barriers were fear of needle and pain, followed by negative perceptions of insulin, emotional barriers and a lack of knowledge or misconception about insulin. Patients' belief that insulin improved their symptoms and the health benefits of insulin were the most frequently cited facilitators to starting insulin. More barriers than facilitators were reported ( Table 3 ). The pattern of barriers and facilitators did not change over time.
Patient-related factors
Insulin-related factors
Eighteen studies reported fear of needle, injection and pain (12, (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) 27, (29) (30) (31) (32) (33) • Insulin can only be administered by injection (93%)
• Patients fearful of insulin therapy (80%)
• Training on insulin is too complicated for patients (58%)
• Follow up for patients on insulin too resource intensive for staff (53%)
• Patients view insulin initiation as a personal failure (53%) Facilitator:
• • Insulin non-initiator (n = 69)
• Current insulin users (n = 100) Not specified
Barriers (for the non-initiator group):
• Risks and benefits not well explained (39%)
• Belief that insulin causes renal failure (32%)
• Difficulty giving insulin due to poor eyesight, shakiness or arthritis (30%) • Seen others deteriorate clinically while on insulin (31%)
• Been advised against insulin by others (19%) Facilitators:
• Home support to administer the insulin (85%) Nakar et al. (29) • Physicians (n = 2681)
• Nurses (n = 1109)
Not specified
Barriers:
• Delay of oral hypoglycaemic medication (NA) • Higher levels of patient adherence (NA) Perceived patients' barriers:
• Self-blame (NA) • Language barrier (41%) Facilitators:
PCPS:
• Failure to reach anti-hyperglycaemic goals using other therapies (83%)
• Medication contraindications (27%)
• Side effects to oral agents (23%)
Tan et al. (23) 0.95
SingHealth Polyclinics, Singapore
Cross-sectional, prospective, interviewer assisted survey. Consecutive sampling: Participants were categorised as 'acceptors' or 'refusors'. 'Refusors' were defined as type 2 diabetics who refused insulin therapy, had been treated with a maximum total daily dose of two or more OHA (either a sulfonylurea and/or biguanide and/or glucosidase inhibitor) and had two consecutive HbA1c readings of greater than 9% in the 6 months prior to the study. 'Acceptors' were type 2 diabetics who had accepted and were on insulin in combination with OHA for at least 6 months prior to recruitment Patients:
• Acceptors (n = 72)
• Refusors (n = 72) 164 (87.8%)
Self-designed questionnaire Barriers:
• Insulin injection is unnecessary; other treatment is available (70.8%)
• Insulin injection indicates an advanced phase of illness (63.9%)
• Use of insulin indicates past failure to care for one's self (55.6%)
• Use of insulin involves painful injections (50.0%)
• Insulin injections involve many everyday hassle (50.0%) Facilitators:
• Insulin injection effectively controls blood glucose levels (59.7%)
• Insulin is more effective than oral medication (43.1%)
• Use of insulin helps one feel better ( • Patients who accept insulin therapy (n = 10)
• Patients who refuse insulin therapy (n = 8) • Doctors (n = 15)
• Nurses (n = 8)
23
Not specified • GPs (n = 4)
• GP nurses (n = 3)
• Nurse diabetes training (n = 3)
• Consultants (n = 2)
• Registrar (n = 1) • Doctors (n = 8)
• Nurses (n = 10)
• Patients (n = 11) • Insulin can only be administered by injection (93%)
• Patients view insulin initiation as a personal failure (53%)
Facilitator:
• • Risks and benefits not well explained (39%)
• Difficulty giving insulin due to poor eyesight, shakiness or arthritis (30%) • Prefer to delay the initiation of insulin therapy until it is absolutely essential (73.6%)
• Not believing that most of their patients with T2DM will eventually need to go on insulin regardless of how well they adhere to their treatment regimen (43%) Nadasen et al. (24) Not specified Not specified • Home support to administer the insulin (85%) Nakar et al. (29) Self-designed questionnaire
• Patients' barriers to insulin therapy (closed questions).
• Physicians' barriers for commencing insulin treatment • Delay of oral hypoglycaemic medication (NA)
• Higher levels of patient adherence (NA)
Perceived patients' barriers:
• Self-blame (NA) • Fear of injection (97%)
• Lack of self-management skills (43%)
• Negative perception of insulin (38%)
• Inconvenience associated with injections and self-monitoring of glucose (22%) PCPs:
• Language barrier (41%) Facilitators:
Tan et al. (23) Self-designed questionnaire
Not specified
No. of items: not specified Response: Likert scale
Patients with T2DM, who refused insulin therapy, had been treated with a maximum total daily dose of two or more OHA and those who had accepted and were on insulin in combination with OHA for at least 6 months
Cross-sectional, prospective, interviewer assisted survey. Consecutive sampling: Participants were categorised as 'acceptors' or 'refusors'. ' Refusors' were defined as type 2 diabetics who refused insulin therapy, had been treated with a maximum total daily dose of two or more OHA (either a sulfonylurea and/or biguanide and/or glucosidase inhibitor) and had two consecutive HbA1c readings of greater than 9% in the 6 months prior to the study. ' Acceptors' were type 2 Barriers:
• Insulin injections involve a lot of everyday hassle (50.0%)
Facilitators:
• Insulin is more effective than oral medication (43.1%) Barriers: Physician-perceived reason for patient resistance:
• 'I don't want to inject myself for the rest of my life' (95%)
• 'Injections are painful' (77%)
• 'Injections are scary' (74%)
• 'I don't want to be bothered with doing injections' (67%)
• 'Insulin will limit my daily life and activities' (59%)
Patients:
• 'Using insulin means my disease is worsening' (90%)
• 'I don't want to be bothered with doing injections' (90%)
• 'Injecting insulin in the presence of others is embarrassing' (81%)
• 'My family will be worried' (76%) T2DM, type 2 diabetes mellitus; OHA, oral hypoglycaemic agent; CME, continuous medical education. (12, 15, 16, 18, (20) (21) (22) 24, 25, 29, 30, 33) . Insulin administration was perceived by patients to be difficult and complicated (15, 17, 18, 20, 22, 24, 31) . Some patients found it hard to adjust insulin dosages (18) , some viewed home monitoring of blood glucose as an additional burden (15, 18, 29) and more painful than insulin injections (29) . Insulin treatment was viewed as inconvenient to patients because they have to carry insulin pen with them and inject regularly (12, 15, 18, 19, (21) (22) (23) 26, 30, 31) . In terms of facilitators, patients who are not afraid of injections (11, 15, 20, 24, 31) and believe that insulin can help improve their blood sugar control, prolong their life, reduce complications and symptoms and is more effective than oral medications, were more likely to start insulin (11, 15, 17, 19, 22, 31, 33) . Having undergone hands-on demonstration of insulin injection was also a facilitator to starting insulin (11, 15, 22, 26) .
Personal factor
Thirteen studies reported negative perceptions on insulin therapy. To patients, insulin initiation signified serious stage of diabetes and considered as a last resort (12, 15, 16, (18) (19) (20) 22, 23, 25, 30, 33) . Some were sceptical about the benefits of insulin (2, 12, 20, 21, 33) while others perceived insulin as unclean, meant for older people and associated with sexual dysfunction in men (21) .
Ten studies reported negative attitudes towards diabetes and its treatment which prevent them from starting insulin. Patients perceived starting insulin as a punishment and personal failure (2, 16, 18, (21) (22) (23) 31) . They also did not believe that there was a need to start insulin (15, 18, 22, 30) . Other negative attitudes include denial towards diabetes (22) , inaccurate perception of treatment goal (31) and fatalistic view about diabetes (12) .
Patients' sociodemographic and clinical profiles were also associated with barriers to insulin initiation and they included: being elderly, lower socioeconomic status, high body mass index, having cardiovascular disease and cultural barriers (12, 13, 18, 20, 25, 33) . Elderly patients were hesitant to initiate insulin if they had poor vision, unsteady hands or arthritis, and if they had little or no social support (18, 25) . Some patients preferred to use other treatment options (25, 34, 35) , including complementary and alternative medicines (25) . On the other hand, patients who were involved in decision making (11, 26, 31) , had poor physical health (15, 31) and perceived that they have no choice (29) were more likely to start insulin.
Social factors
Seven studies indicated that stigma and discrimination are barriers to starting insulin (12, 13, 15, 21, 22, 30, 31) . Other social barriers include interference with social and work activities (18, 20, 25, 33 ), family's and peers' negative views and experiences (13, 24, 30, 31) , loss of independence (12, 22) , lack of social support (14) and affecting relationship with significant others (25) . Social factors that facilitated insulin initiation include positive experiences of others (22, 31) and support from family (13, 24, 31) , peer (13, 15) and healthcare providers (14, 23) .
Healthcare professional factors
Lack of knowledge and skills were the most commonly reported barrier to insulin initiation among the healthcare professionals (16, 18, 22, (26) (27) (28) (29) 32, 33) . Other barriers included lack of good doctor-patient relationships (16, 18, 26, 29) and communication (13, 18, 19, 22, 25) , not engaging patients in decision making (15) , paternalistic attitude (13, 16) and healthcare professionals' inertia and negative attitudes towards insulin (2, 22, 25, 29, 33) . The review found that healthcare professionals who had adequate knowledge and skills (2, 26, 27) , effective communication skills (17, 29) and who involved patients in decision making (14, 15) were more likely to initiate insulin with their patients.
System factors
Lack of time (22, 26, 33) was the most common barrier to starting insulin. This was due to high patient load (13, 22) , time needed for patient to deliberate the decision (13) and for insulin dose adjustment (32) . The following system facilitators were identified: availability of patient information and education (11, 14, 22, 26, 33) , trained staff (13, 16, 26) , regular follow-up via clinic visits or telephone calls (15) , initiating insulin in primary care (vs. secondary care) (10) , and referral to specialists (29) .
Discussion
This systematic review documented the range of barriers and facilitators patients face during insulin initiation. By including both quantitative and qualitative studies, this systematic review managed to identify a range of factors (patient-related, healthcare professional, and system factors) that the healthcare professionals should consider when advising patients with type 2 diabetes on insulin treatment.
The key barriers to insulin initiation in patient with type 2 diabetes appear to be patient-related factors. Fear of pain and needles, concern about the side effects of insulin and the complexity of delivering the insulin remain major hurdles in insulin initiation. This is despite marked improvement in the delivery process (36) , development of newer insulin with better safety profile (37) and newer glucose-lowering drugs such as glucagon-like peptide 1 receptor agonists which have fewer side effects (38) . Patients perceived starting insulin as an indication of advanced stage of diabetes, which may lead to complications such as renal failure. These misconceptions cause delay in patient's decision to start insulin. Patients also 'blamed' themselves for failing to control their diabetes and some perceived insulin therapy as a punishment. These negative emotions could be avoided by explaining to patients that the need for insulin therapy is part of the disease progression (1), preferably at the early stage of the illness rather than at the point of decision making (39) . Another key barrier concerns the healthcare professionals' ability to guide patients in making decisions about starting insulin. Those who lack knowledge and have poor communication skills might face difficulty counselling patients on insulin treatment.
On the other hand, the main facilitators focus on the clinical benefits of insulin in reducing symptoms and complications as well as improving survival and quality of life. Providing patients with accurate health information and education can help to make a more informed decision about starting insulin therapy. In addition, system factors such as providing adequate time for a consultation and regular follow-up may allow patients and healthcare professionals to discuss their concerns and expectations. Decision support tools such as a patient decision aid may be helpful to overcome this barrier. (40) This systematic review included studies which surveyed or interviewed patients who were at different stages of decision making. The barriers and facilitators faced by insulin-na€ ıve patients might be different from those who have already started insulin. There might be recall bias for insulin users and patients who have already started on insulin might rationalise their decision by playing down the harms. Therefore, we have excluded them from this review. Patients and healthcare professionals have different views on which barriers and facilitators are more relevant to the patients. While healthcare professionals emphasise on patients' concerns about side effects of insulin and injections, patients were also worried about the lack of social support and emotional impact. Therefore, there is a need for the healthcare professional to ask patients about their concerns and address them accordingly as their concerns are often different from those assumed by the healthcare professionals (10, 14, 15, 17, 25, (27) (28) (29) .
A limitation of our review was that we only included English articles. Future systematic reviews may consider expanding to include other languages.
Conclusion
This systematic review has identified several barriers that influence insulin initiation in patients with type 2 diabetes: patient-related, healthcare professional, and system factors. The main barriers identified are fear of pain and injection, concerns about side effects of insulin, perception that insulin indicated end stage of diabetes and inconvenience. Facilitators to insulin initiation were reducing symptoms, complications and improving survival and quality of life. When counselling patients who are considering insulin, it is important to explore the barriers faced by patients ª 2015 John Wiley & Sons Ltd Int J Clin Pract and to address them accordingly. This will help patients make an informed decision about their diabetes treatment.
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